U.S. markets close in 56 minutes
  • S&P 500

    3,894.73
    -17.01 (-0.43%)
     
  • Dow 30

    31,390.49
    -110.19 (-0.35%)
     
  • Nasdaq

    11,519.10
    -88.52 (-0.76%)
     
  • Russell 2000

    1,777.87
    +12.14 (+0.69%)
     
  • Crude Oil

    109.38
    +1.76 (+1.64%)
     
  • Gold

    1,824.50
    -5.80 (-0.32%)
     
  • Silver

    21.12
    0.00 (0.00%)
     
  • EUR/USD

    1.0582
    +0.0023 (+0.22%)
     
  • 10-Yr Bond

    3.2020
    +0.0770 (+2.46%)
     
  • GBP/USD

    1.2272
    +0.0002 (+0.01%)
     
  • USD/JPY

    135.4610
    +0.2910 (+0.22%)
     
  • BTC-USD

    20,817.94
    -380.46 (-1.79%)
     
  • CMC Crypto 200

    454.02
    -7.77 (-1.68%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Ocugen, Inc. to Present at BIO International Convention 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Ocugen
Ocugen

MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that Michael Shine, Ocugen’s Senior Vice President, Commercial, will present at the 2022 BIO International Convention being held in San Diego, California, from June 13-16, 2022.

The Company presentation, which is scheduled for Monday, June 13, at 4:45 p.m. PT in Meeting Room 1 of the San Diego Convention Center, will focus on Ocugen’s robust clinical pipeline, including its COVID-19 vaccine candidate, COVAXIN™ (BBV152), its modifier gene therapy programs, and its new cell therapy program, NeoCart®.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent / Daniel Kontoh-Boateng (Investor)
jnugent@tiberend.com
dboateng@tiberend.com

Dave Schemelia (Media)
dschemelia@tiberend.com